Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.33) by 54.55 percent. This is a 75.6 percent increase over losses of $(2.09) per share from the same period last year. The company reported quarterly sales of $3.08 million which missed the analyst consensus estimate of $3.32 million by 7.12 percent. This is a 77.52 percent increase over sales of $1.74 million the same period last year.